PYXS News and Press, Pyxis Oncology Inc. From 05/30/23

First subject dosed in Phase 1 trial of PYX-106, a fully human immunotherapy antibody candidate Second dose level initiated in Phase 1 trial of PYX-201, an antibody-drug conjugate (ADC) candidate Preliminary data from both trials on track for late-2023/early-2024 timeframe ...

2023-05-24 15:59:57 ET Acquisitions are always an exciting time, especially when one (or both) parties involved are publicly traded entities. That’s exactly what happened on Wednesday after it was announced that %PyxisOncology (Nasdaq: $PYXS) agreed to acquire %Apexigen (Nasd...

2023-05-24 10:07:34 ET Gainers: Enveric Biosciences ( ENVB ) +100% . Zura Bio ( ZURA ) +37% . Kamada ( KMDA ) +19% . Organogenesis ( ORGO ) +16% . OptimizeRx ( OPRX ) +14% . Losers: PTC Therapeutics ( PTCT ) -24% ....

Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotiga...

2023-05-18 17:35:14 ET Gainers: Brightcove  ( BCOV ) +6% . GSI Technology ( GSIT ) +5% . Clarus  ( CLAR ) +4% . Pyxis Oncology ( PYXS ) +4% . Atara Biotherapeutics ( ATRA ) +2% . Losers: CrowdStrike Holdings ( ...

2023-05-18 18:38:14 ET Gainers: Farfetch Limited ( FTCH ) +18% . Ouster ( OUST ) +9%. Guardforce AI ( GFAI ) +4% . GSI Technology ( GSIT ) +4%. Losers: CaliberCos ( CWD ) -9%. Flowers Foods ( FLO ) -5%. DXC Te...

2023-05-15 13:03:03 ET Penny stocks are sought after for their potential to explode to extreme levels. Look at a company we discussed roughly one month ago, Ohmyhome Ltd ( NASDAQ: OMH ). In the article 3 Hot Penny Stocks To Watch Today; Is It Time To Buy? OMH stock was discussed sho...

2023-05-11 10:02:43 ET Pyxis Oncology press release ( NASDAQ: PYXS ): Q1 GAAP EPS of -$0.54 beats by $0.39 . Pyxis Oncology ended the first quarter of 2023 with approximately $150.8 million in cash, cash equivalents, restricted cash and short-term investments, which is...

Orphan Drug Designation received for PYX-201 in pancreatic cancer Preliminary data from two Phase 1 trials anticipated late 2023 to early 2024 Strong balance sheet with $150.8 million in cash (including restricted cash) and short-term investments and no debt supports operations ...

2023-04-04 10:04:33 ET Gainers: Bullfrog AI ( BFRG ) +89% . Butterfly Network ( BFLY ) +26% . Mangoceuticals ( MGRX ) +14% . Encompass Health ( EHC ) +11% . HUTCHMED (China) ( HCM ) +10% . Losers: Clearmind Medicine ( CM...